Global Chikungunya Rapid Testing Market

Chikungunya Rapid Testing Comprehensive Study by Technique (Serological testing techniques, Molecular testing techniques), End User (Hospitals, Academic Institutes, Diagnostic Centres, Research Institutes, Biotechnology Companies) Players and Region - Global Market Outlook to 2028

Chikungunya Rapid Testing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Chikungunya Rapid Testing?
The market for chikungunya quick testing is primarily driven by the increased incidence of chikungunya around the world, expanding public awareness of mosquito-transmitted illnesses, and government activities aimed at preventing and controlling mosquito infestation and sickness. The quick increase in Chikungunya research and development by numerous experts are playing a major role in the rapid rise of Chikungunya's rapid testing.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledQuest Diagnostics Incorporated (United States), Alere (United States), Genome Diagnostics Pvt. Ltd. (India), Bio-Rad Laboratories Inc. (United States), Taj Pharmaceuticals Limited (India), Inbios India (India), Medical Innovation Ventures (Malaysia), Lumiquick Diagnostics Inc. (United States) and Etubics Corporation (United States)


The study covers a detailed analysis segmented by key business segments i.e. and major geographies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Chikungunya Rapid Testing market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Chikungunya Rapid Testing market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Quest Diagnostics Incorporated (United States), Alere (United States), Genome Diagnostics Pvt. Ltd. (India), Bio-Rad Laboratories Inc. (United States), Taj Pharmaceuticals Limited (India), Inbios India (India), Medical Innovation Ventures (Malaysia), Lumiquick Diagnostics Inc. (United States) and Etubics Corporation (United States).

Market Overview:
In April 2021, Select Health of South Carolina and Quest Diagnostics announced they have collaborated to expand Select Health’s laboratory network for its Medicaid and Medicare Medicaid dual-eligible enrollees.
The regulatory bodies responsible for Chikungunya rapid testing may differ depending on the country or region. In the United States, for example, the Food and Drug Administration (FDA) regulates diagnostic tests, including rapid tests for infectious diseases like Chikungunya.
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Influencing Trend:
Rapidly Increasing Research and Development on Chikungunya by Various Scientists

Market Growth Drivers:
Rising Incidence of Chikungunya in the World and Government Initiatives Regarding the Prevention and Control of Mosquito Infestation and the Disease

Challenges:
Lack of Appropriate Treatment and Vaccines and Lack of Awareness in Certain Underdeveloped Countries

Restraints:
Misdiagnosis of Chikungunya with Dengue and Zika Virus Infections

Opportunities:
Increasing Awareness among People Towards Mosquito-Transmitted Infections and Rising Unmet Needs for Chikungunya Diagnosis in Asia And Africa

Key highlights of the Global Chikungunya Rapid Testing market Study:
• CAGR of the market during the forecast period 2022-2028
• In-depth information on growth factors that will accelerate the Chikungunya Rapid Testing market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Chikungunya Rapid Testing market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Chikungunya Rapid Testing Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Chikungunya Rapid Testing market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Chikungunya Rapid Testing market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Chikungunya Rapid Testing Provider, Government Regulatory and Research Organizations, End-Use Industries and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Technique
  • Serological testing techniques
  • Molecular testing techniques

By End User
  • Hospitals
  • Academic Institutes
  • Diagnostic Centres
  • Research Institutes
  • Biotechnology Companies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Chikungunya in the World
      • 3.2.2. Government Initiatives Regarding the Prevention and Control of Mosquito Infestation and the Disease
    • 3.3. Market Challenges
      • 3.3.1. Lack of Appropriate Treatment and Vaccines
      • 3.3.2. Lack of Awareness in Certain Underdeveloped Countries
    • 3.4. Market Trends
      • 3.4.1. Rapidly Increasing Research and Development on Chikungunya by Various Scientists
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Chikungunya Rapid Testing, by Technique, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Chikungunya Rapid Testing (Value)
      • 5.2.1. Global Chikungunya Rapid Testing by: Technique (Value)
        • 5.2.1.1. Serological testing techniques
        • 5.2.1.2. Molecular testing techniques
      • 5.2.2. Global Chikungunya Rapid Testing by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Academic Institutes
        • 5.2.2.3. Diagnostic Centres
        • 5.2.2.4. Research Institutes
        • 5.2.2.5. Biotechnology Companies
      • 5.2.3. Global Chikungunya Rapid Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Chikungunya Rapid Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Quest Diagnostics Incorporated (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alere (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genome Diagnostics Pvt. Ltd. (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taj Pharmaceuticals Limited (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Inbios India (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Medical Innovation Ventures (Malaysia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lumiquick Diagnostics Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Etubics Corporation (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Chikungunya Rapid Testing Sale, by Technique, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Chikungunya Rapid Testing (Value)
      • 7.2.1. Global Chikungunya Rapid Testing by: Technique (Value)
        • 7.2.1.1. Serological testing techniques
        • 7.2.1.2. Molecular testing techniques
      • 7.2.2. Global Chikungunya Rapid Testing by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Academic Institutes
        • 7.2.2.3. Diagnostic Centres
        • 7.2.2.4. Research Institutes
        • 7.2.2.5. Biotechnology Companies
      • 7.2.3. Global Chikungunya Rapid Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Chikungunya Rapid Testing: by Technique(USD Million)
  • Table 2. Chikungunya Rapid Testing Serological testing techniques , by Region USD Million (2017-2022)
  • Table 3. Chikungunya Rapid Testing Molecular testing techniques , by Region USD Million (2017-2022)
  • Table 4. Chikungunya Rapid Testing: by End User(USD Million)
  • Table 5. Chikungunya Rapid Testing Hospitals , by Region USD Million (2017-2022)
  • Table 6. Chikungunya Rapid Testing Academic Institutes , by Region USD Million (2017-2022)
  • Table 7. Chikungunya Rapid Testing Diagnostic Centres , by Region USD Million (2017-2022)
  • Table 8. Chikungunya Rapid Testing Research Institutes , by Region USD Million (2017-2022)
  • Table 9. Chikungunya Rapid Testing Biotechnology Companies , by Region USD Million (2017-2022)
  • Table 10. South America Chikungunya Rapid Testing, by Country USD Million (2017-2022)
  • Table 11. South America Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 12. South America Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 13. Brazil Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 14. Brazil Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 15. Argentina Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 16. Argentina Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 17. Rest of South America Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 18. Rest of South America Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 19. Asia Pacific Chikungunya Rapid Testing, by Country USD Million (2017-2022)
  • Table 20. Asia Pacific Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 21. Asia Pacific Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 22. China Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 23. China Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 24. Japan Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 25. Japan Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 26. India Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 27. India Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 28. South Korea Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 29. South Korea Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 30. Taiwan Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 31. Taiwan Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 32. Australia Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 33. Australia Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 34. Rest of Asia-Pacific Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 36. Europe Chikungunya Rapid Testing, by Country USD Million (2017-2022)
  • Table 37. Europe Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 38. Europe Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 39. Germany Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 40. Germany Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 41. France Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 42. France Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 43. Italy Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 44. Italy Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 45. United Kingdom Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 46. United Kingdom Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 47. Netherlands Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 48. Netherlands Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 49. Rest of Europe Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 50. Rest of Europe Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 51. MEA Chikungunya Rapid Testing, by Country USD Million (2017-2022)
  • Table 52. MEA Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 53. MEA Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 54. Middle East Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 55. Middle East Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 56. Africa Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 57. Africa Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 58. North America Chikungunya Rapid Testing, by Country USD Million (2017-2022)
  • Table 59. North America Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 60. North America Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 61. United States Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 62. United States Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 63. Canada Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 64. Canada Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 65. Mexico Chikungunya Rapid Testing, by Technique USD Million (2017-2022)
  • Table 66. Mexico Chikungunya Rapid Testing, by End User USD Million (2017-2022)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Chikungunya Rapid Testing: by Technique(USD Million)
  • Table 77. Chikungunya Rapid Testing Serological testing techniques , by Region USD Million (2023-2028)
  • Table 78. Chikungunya Rapid Testing Molecular testing techniques , by Region USD Million (2023-2028)
  • Table 79. Chikungunya Rapid Testing: by End User(USD Million)
  • Table 80. Chikungunya Rapid Testing Hospitals , by Region USD Million (2023-2028)
  • Table 81. Chikungunya Rapid Testing Academic Institutes , by Region USD Million (2023-2028)
  • Table 82. Chikungunya Rapid Testing Diagnostic Centres , by Region USD Million (2023-2028)
  • Table 83. Chikungunya Rapid Testing Research Institutes , by Region USD Million (2023-2028)
  • Table 84. Chikungunya Rapid Testing Biotechnology Companies , by Region USD Million (2023-2028)
  • Table 85. South America Chikungunya Rapid Testing, by Country USD Million (2023-2028)
  • Table 86. South America Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 87. South America Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 88. Brazil Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 89. Brazil Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 90. Argentina Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 91. Argentina Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 92. Rest of South America Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 93. Rest of South America Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 94. Asia Pacific Chikungunya Rapid Testing, by Country USD Million (2023-2028)
  • Table 95. Asia Pacific Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 96. Asia Pacific Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 97. China Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 98. China Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 99. Japan Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 100. Japan Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 101. India Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 102. India Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 103. South Korea Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 104. South Korea Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 105. Taiwan Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 106. Taiwan Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 107. Australia Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 108. Australia Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 109. Rest of Asia-Pacific Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 110. Rest of Asia-Pacific Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 111. Europe Chikungunya Rapid Testing, by Country USD Million (2023-2028)
  • Table 112. Europe Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 113. Europe Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 114. Germany Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 115. Germany Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 116. France Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 117. France Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 118. Italy Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 119. Italy Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 120. United Kingdom Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 121. United Kingdom Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 122. Netherlands Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 123. Netherlands Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 124. Rest of Europe Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 125. Rest of Europe Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 126. MEA Chikungunya Rapid Testing, by Country USD Million (2023-2028)
  • Table 127. MEA Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 128. MEA Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 129. Middle East Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 130. Middle East Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 131. Africa Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 132. Africa Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 133. North America Chikungunya Rapid Testing, by Country USD Million (2023-2028)
  • Table 134. North America Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 135. North America Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 136. United States Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 137. United States Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 138. Canada Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 139. Canada Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 140. Mexico Chikungunya Rapid Testing, by Technique USD Million (2023-2028)
  • Table 141. Mexico Chikungunya Rapid Testing, by End User USD Million (2023-2028)
  • Table 142. Research Programs/Design for This Report
  • Table 143. Key Data Information from Secondary Sources
  • Table 144. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Chikungunya Rapid Testing: by Technique USD Million (2017-2022)
  • Figure 5. Global Chikungunya Rapid Testing: by End User USD Million (2017-2022)
  • Figure 6. South America Chikungunya Rapid Testing Share (%), by Country
  • Figure 7. Asia Pacific Chikungunya Rapid Testing Share (%), by Country
  • Figure 8. Europe Chikungunya Rapid Testing Share (%), by Country
  • Figure 9. MEA Chikungunya Rapid Testing Share (%), by Country
  • Figure 10. North America Chikungunya Rapid Testing Share (%), by Country
  • Figure 11. Global Chikungunya Rapid Testing share by Players 2022 (%)
  • Figure 12. Global Chikungunya Rapid Testing share by Players (Top 3) 2022(%)
  • Figure 13. Global Chikungunya Rapid Testing share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Quest Diagnostics Incorporated (United States) Revenue, Net Income and Gross profit
  • Figure 16. Quest Diagnostics Incorporated (United States) Revenue: by Geography 2022
  • Figure 17. Alere (United States) Revenue, Net Income and Gross profit
  • Figure 18. Alere (United States) Revenue: by Geography 2022
  • Figure 19. Genome Diagnostics Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 20. Genome Diagnostics Pvt. Ltd. (India) Revenue: by Geography 2022
  • Figure 21. Bio-Rad Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bio-Rad Laboratories Inc. (United States) Revenue: by Geography 2022
  • Figure 23. Taj Pharmaceuticals Limited (India) Revenue, Net Income and Gross profit
  • Figure 24. Taj Pharmaceuticals Limited (India) Revenue: by Geography 2022
  • Figure 25. Inbios India (India) Revenue, Net Income and Gross profit
  • Figure 26. Inbios India (India) Revenue: by Geography 2022
  • Figure 27. Medical Innovation Ventures (Malaysia) Revenue, Net Income and Gross profit
  • Figure 28. Medical Innovation Ventures (Malaysia) Revenue: by Geography 2022
  • Figure 29. Lumiquick Diagnostics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Lumiquick Diagnostics Inc. (United States) Revenue: by Geography 2022
  • Figure 31. Etubics Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 32. Etubics Corporation (United States) Revenue: by Geography 2022
  • Figure 33. Global Chikungunya Rapid Testing: by Technique USD Million (2023-2028)
  • Figure 34. Global Chikungunya Rapid Testing: by End User USD Million (2023-2028)
  • Figure 35. South America Chikungunya Rapid Testing Share (%), by Country
  • Figure 36. Asia Pacific Chikungunya Rapid Testing Share (%), by Country
  • Figure 37. Europe Chikungunya Rapid Testing Share (%), by Country
  • Figure 38. MEA Chikungunya Rapid Testing Share (%), by Country
  • Figure 39. North America Chikungunya Rapid Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Quest Diagnostics Incorporated (United States)
  • Alere (United States)
  • Genome Diagnostics Pvt. Ltd. (India)
  • Bio-Rad Laboratories Inc. (United States)
  • Taj Pharmaceuticals Limited (India)
  • Inbios India (India)
  • Medical Innovation Ventures (Malaysia)
  • Lumiquick Diagnostics Inc. (United States)
  • Etubics Corporation (United States)
Select User Access Type

Key Highlights of Report


May 2023 155 Pages 54 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Chikungunya Rapid Testing Market Quantitative research analysis
Global Chikungunya Rapid Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Chikungunya Rapid Testing Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Chikungunya Rapid Testing market is dominated by United States Players and may generate healthy valuation by 2028.
  • Rising Incidence of Chikungunya in the World
  • Government Initiatives Regarding the Prevention and Control of Mosquito Infestation and the Disease
dominated the Chikungunya Rapid Testing market. This is attributable to growing trend of "Rapidly Increasing Research and Development on Chikungunya by Various Scientists"

Know More About Global Chikungunya Rapid Testing Market Report?

Have a Query? Click Here

Other Related Reports

Homeopathic Injectable Comprehensive Study by Sales Channels (Online Sales Channel, Offline Sales Channels), Types of administration (Subcutaneous Administration, Intraarticular Administration, Peri...
$ 3350
Guided Bone Regeneration Comprehensive Study by Type (Ceramic-based, Polymer-based, Growth factor-based, Cell-based, Others), Application (Orthopedic Surgery, Bone Trauma, Dental Surgery, Others), En...
$ 3650
Electronic Prescription Service Comprehensive Study by Type (Integrated Solutions, Standalone Solutions), Deployment Mode (Cloud-Based, On-Premise), End- User (Hospitals, Office-based Physicians, Pha...
$ 3450
Pets Telehealth - Comprehensive Study by Application (Household, Veterinary Clinics), Platform (IOS, Android), Pricing (Monthly Subscription, Annual Subscription), Features (Virtual consultations, Te...
$ 3450
Endophthalmitis Treatment Comprehensive Study by Type (Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}, Endog...
$ 3650
Medical Second Opinion Services- Comprehensive Study by Application (Patients, Families), Service providers (Hospitals, Medical second opinion providing companies, Health insurance companies), Diseas...
$ 3650